Exemplos de uso de Glucose-lowering em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
The clinical significance of the glucose-lowering effect of M1 is unclear.
Average glucose-lowering effect over 6 hours in 20 patients with type 1 diabetes mellitus.
A distinctive feature of this adaptogen is a strong glucose-lowering effect.
Day-to-day variability in glucose-lowering effect from 2- 24 hours AUCGIR2-24h, SS.
Your doctor may prescribe Vokanamet together with another glucose-lowering medicine.
This resulted in a blood glucose-lowering effect throughout the meal period.
Canagliflozin as add-on therapy to insulin with or without other glucose-lowering medicinal products.
Day-to-day variability in glucose-lowering effect during one dosing interval AUCGIR, τ, SS.
For patients inadequately controlled on metformin monotherapy ormetformin in combination with other glucose-lowering medicinal products including insulin.
Total glucose-lowering effect of Tresiba increases linearly with increasing doses.
Restrictions on compatibility with insulin, glucose-lowering drugs, diuretics in Losartan not.
Total glucose-lowering effect is comparable for Tresiba 100 units/mL and 200 units/mL after administration of same doses of the two products.
However, an overdose may result in an exaggerated glucose-lowering effect, with the development of hypoglycaemic symptoms.
If a different glucose-lowering treatment is started after the discontinuation of prolonged-release exenatide, consideration should be given to the prolonged release of the product see section 5.2.
Alibertia edulis(cerrado quince, rubiaceae) is commonly used for its medicinal properties, such as glucose-lowering, diuretic, soothing, and antihypertensive activities.
In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control see sections 4.4, 4.5 and 5.1 for available data on different combinations.
The recommended dose is 10 mg dapagliflozin once daily for monotherapy andadd-on combination therapy with other glucose-lowering medicinal products including insulin.
The endocrinologist will adjust the doses of glucose-lowering agents- he should be informed about the treatment with thiazide diuretic hydrochlorothiazide.
Patients should be alerted to the risk of hypoglycaemia when this medicinal product is used in combination with other glucose-lowering medicinal products known to cause hypoglycaemia.
In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control see section 4.4 and 5.1 for available data on different combinations.
Prandin produced a good insulin response to a meal within 30 minutes of being dosed in type 2 diabetes patients,leading to a blood glucose-lowering effect throughout the meal.
Half-life was prolonged from 1.3 hr to 3.7 hr, resulting in possibly enhanced andprolonged blood glucose-lowering effect of repaglinide, and plasma repaglinide concentration at 7 hr was increased 28.6-fold by gemfibrozil.
The co-administration of canagliflozin and metformin has been studied in patients with type 2 diabetes inadequately controlled on metformin either alone orin combination with other glucose-lowering medicinal products.
Years of age and 46 patients 75 years of age to≤ 80 years of age with inadequate glycaemic control on current diabetes treatment(glucose-lowering medicinal products and/or diet and exercise) participated in a double-blind, placebo-controlled study over 26 weeks.
In combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products(see sections 4.4, 4.5 and 5.1 for available data on different combinations) in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.
Our results point to a new biological effect of jabuticaba, a Brazilian native specimenthat has important biological effects on the cardiovascular system, such as glucose-lowering, lipid-lowering and hypotensive effects.
Recently, the RECORD study demonstrated that the addition of rosiglitazone to glucose-lowering therapy in individuals with type 2 diabetes increases the risk of heart failure, but not the risk of overall cardiovascular morbidity or mortality,when compared with standard glucose-lowering drugs.
As hypoglycaemia in this study was avoidedthrough increased calorie intake, a relative overdose may result in an exaggerated glucose-lowering effect with development of hypoglycaemic symptoms dizziness, sweating, tremor, headache etc.
In patients on their maximally tolerated doses of metformin along with other glucose-lowering medicinal products including insulin, when these do not provide adequate glycaemic control(see sections 4.4, 4.5, and 5.1 for available data on different add-on therapies) in patients already being treated with the combination of canagliflozin and metformin as separate tablets.
Patients not adequately controlled on metformin alone orin combination with other glucose-lowering medicinal products, including insulin, should receive a total daily dose of Ebymect equivalent to dapagliflozin 10 mg, plus the total daily dose of metformin, or the nearest therapeutically appropriate dose, already being taken.